Ekso Bionics (EKSO)
(Delayed Data from NSDQ)
$1.06 USD
+0.04 (3.92%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.07 +0.01 (0.94%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.06 USD
+0.04 (3.92%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.07 +0.01 (0.94%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 0.00% and 22.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?
by Zacks Equity Research
Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.
What Makes Ekso Bionics (EKSO) a New Buy Stock
by Zacks Equity Research
Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -25.00% and -9.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -22.22% and -10.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) in Focus: Stock Moves 6.6% Higher
by Kaibalya Pravo Dey
Ekso Bionics (EKSO) shares rose nearly 7% in the last trading session, amid huge volumes.
Options Traders Expect Huge Moves in Ekso Bionics (EKSO) Stock
by Zacks Equity Research
Ekso Bionics (EKSO) needs investors to pay close attention to the stock based on moves in the options market lately.
Can The Uptrend Continue for Ekso Bionics Holdings (EKSO)?
by Zacks Equity Research
Investors certainly have to be happy with Ekso Bionics Holdings, Inc. (EKSO) and its short term performance
Why Trump Could Still Be a Threat to Medical Device Stocks
by Zacks Equity Research
The Republican healthcare bill, American Health Care Act (ACHA), which was released earlier this month with the target to repeal the Affordable Care Act (ACA), hasn't found favor with the masses.